Retina (Philadelphia, Pa.) · 2026
EFFECTS OF SOCIOECONOMIC FACTORS ON VISUAL OUTCOME AND MANAGEMENT OF PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Barthelemy Normila, Tailor Prashant, Sridhar Jayanth, Samarakoon Thilani, Sengillo Jesse D
Аннотация
PURPOSE: To analyze the relationship between socioeconomic status and neovascular age-related macular degeneration outcomes and management.
METHODS: Retrospective analysis of 1,449 patients diagnosed with neovascular age-related macular degeneration, treated with anti-vascular endothelial growth factor between January 2016 and January 2024.
RESULTS: Lower income was associated with poorer baseline ( P < 0.001) and final ( P < 0.001) best-corrected visual acuity. Worse final visual acuity correlated with lower baseline best-corrected visual acuity ( P < 0.001), lower income ( P = 0.05), and older age ( P < 0.001); insurance type did not ( P = 0.558). Non-Hispanic/non-Latino patients exhibited a higher rate of delayed injections per scheduled visit than Hispanics ( P =0.002). Ethnicity correlated with insurance status ( P = 0.008); Hispanic or Latino patients more often had Medicaid or commercial insurance; non-Hispanics/non-Latino patients more often had Medicare. Higher-income patients were more likely to receive aflibercept ( P < 0.001) and faricimab ( P =0.021). Hispanic or Latino were more likely to receive bevacizumab (OR 2.49; P < 0.001), but insurance type modified this association (OR 3.42; P = 0.010).
CONCLUSION: Lower income correlated with worse neovascular age-related macular degeneration visual outcomes, and the type of anti-vascular endothelial growth factor treatment used varied across income and ethnicity groups, but not insurance type.
METHODS: Retrospective analysis of 1,449 patients diagnosed with neovascular age-related macular degeneration, treated with anti-vascular endothelial growth factor between January 2016 and January 2024.
RESULTS: Lower income was associated with poorer baseline ( P < 0.001) and final ( P < 0.001) best-corrected visual acuity. Worse final visual acuity correlated with lower baseline best-corrected visual acuity ( P < 0.001), lower income ( P = 0.05), and older age ( P < 0.001); insurance type did not ( P = 0.558). Non-Hispanic/non-Latino patients exhibited a higher rate of delayed injections per scheduled visit than Hispanics ( P =0.002). Ethnicity correlated with insurance status ( P = 0.008); Hispanic or Latino patients more often had Medicaid or commercial insurance; non-Hispanics/non-Latino patients more often had Medicare. Higher-income patients were more likely to receive aflibercept ( P < 0.001) and faricimab ( P =0.021). Hispanic or Latino were more likely to receive bevacizumab (OR 2.49; P < 0.001), but insurance type modified this association (OR 3.42; P = 0.010).
CONCLUSION: Lower income correlated with worse neovascular age-related macular degeneration visual outcomes, and the type of anti-vascular endothelial growth factor treatment used varied across income and ethnicity groups, but not insurance type.
Предметные рубрики MeSH
HumansRetrospective StudiesWet Macular DegenerationMaleVisual AcuityFemaleAngiogenesis InhibitorsAgedIntravitreal InjectionsVascular Endothelial Growth Factor ABevacizumabSocioeconomic FactorsAged, 80 and overRanibizumabReceptors, Vascular Endothelial Growth FactorMiddle AgedFollow-Up StudiesRecombinant Fusion ProteinsTreatment OutcomeUnited States